β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI)

Request For Quotation
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Suppliers list
Company Name: Shanghai Fuhe Chemistry Technology Co., Ltd.  
Tel: 0086-21-67651709
Email: cfx759@hotmail.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: BOC Sciences  
Tel: 16314854226
Email: info@bocsci.com
Company Name: Suzhou Meishi Biotechnology Co., Ltd.  
Tel: 1173954148q
Email: meishipharma@126.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn

β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) manufacturers

  • Atigliflozin
  • Atigliflozin pictures
  • $1980.00
  • 2026-04-21
  • CAS:647834-15-9
  • Purity:
  • Supply Ability: 10g
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Basic information
Product Name:β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI)
Synonyms:β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI);(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]thiophen-3-yl]oxyoxane-3,4,5-triol;β-D-Glucopyranoside, 2-[(4-methoxyphenyl)methyl]-3-thienyl;Atigliflozin;(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-((2-(4-methoxybenzyl)thiophen-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triol
CAS:647834-15-9
MF:C18H22O7S
MW:382.43
EINECS:
Product Categories:
Mol File:647834-15-9.mol
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Structure
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Chemical Properties
Safety Information
MSDS Information
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Usage And Synthesis
UsesAtigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1].
in vivo

AVE2268 (1-300 mg/kg, p.o.) causes a dose-dependent increase of urinary glucose excretion (UGE) in mice and rats[2].
AVE2268 (10-100 mg/kg, p.o.) dose-dependently decreases blood glucose excursions after glucose (i.p. or p.o.) administration in mice[2].

IC 50hSGLT2: 10 nM (IC50); hSGLT1: 8.2 μM (IC50)
References[1] Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. DOI:10.1002/jlcr.3869
[2] Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. DOI:10.1055/s-0031-1296559
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Preparation Products And Raw materials
Tag:β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI)(647834-15-9) Related Product Information
β-D-Glucopyranoside, 2-[(4-Methoxyphenyl)Methyl]-3-thienyl (9CI) Canagliflozin Ipragliflozin KGA2727 Ertugliflozin Mizagliflozin